卡培他滨用于晚期转移性结肠癌维持性化疗中对患者KPS评分及不良反应的影响

Capecitabine used in terminal maintenance chemotherapy for metastatic colon cancer patients KPS score and the impact of adverse reactions

目的探讨晚期转移性结肠癌维持性化疗中卡培他滨的应用价值.方法选取2021年1月-2023年5月昆明市中医医院收治的96例晚期转移性结肠癌者,采用随机数字表法均分为对照组和研究组各48例.对照组给予FOLFOX治疗,研究组给予奥沙利铂联合卡培他滨治疗,比较两组疗效,治疗前、后的血清肿瘤标志物,功能状态评分和不良反应情况.结果研究组总有效率和疾病控制率均高于对照组,差异有统计学意义(P<0.05);研究组治疗后CEA、CA19-9指标水平均低于对照组,差异有统计学意义(P<0.05);研究组治疗后6周、12周的KPS评分均高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05).结论在晚期转移性结肠癌维持化疗中,卡培他滨的应用可以提高患者总有效率和疾病控制率,降低血清肿瘤标志物CEA和CA19-9水平,改善患者功能状态评分,降低不良反应发生率,临床应用价值较高.

Objective To investigate the application value of capecitabine in maintenance chemotherapy for advanced metastatic colon cancer.Methods A total of 96 patients with advanced metastatic colon cancer admitted to Kunming Hospital of Traditional Chinese Medicine from January 2021 to May 2023 were selected and divided into control group and study group by random number table method,with 48 cases in each group.Control group given FOLFOX treatment,the study group giving oxaliplatin into joint capecitabine treatment,compare the curative effect of two groups,before and after treatment in the serum tumor markers,function score and adverse reactions.Results The study group total effective rate and disease control rates are higher than the control group,the difference was statistically significant(P<0.05).After treatment,the indexes of CEA and CA19-9 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After 6 weeks and 12 weeks of treatment,the KPS scores of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<O.05).Conclusion Maintain chemotherapy in advanced metastatic colon cancer,the application of capecitabine can improve patients with total effective rate and disease control rates,lower levels of serum tumor markers CEA and CA19-9,to improve the function status of patients,reduce the incidence of adverse reactions,higher clinical value.